HONG KONG – Splisense Ltd. has closed a $28.5 million series B financing that it said will support pipeline development including its lead antisense oligonucleotide candidate, SPL84-23, for the potential treatment of cystic fibrosis. The Jerusalem-based company, which develops mRNA-altering therapies for CF and other genetic pulmonary diseases, attracted support for the round from Orbimed, Israel Biotech Fund, Biotel Ltd. and the Cystic Fibrosis Foundation.
Shanghai-based Elpiscience Biopharmaceuticals Co. Ltd. raised $105 million in a series C financing round to move candidates, starting with an anti-CD39 antibody, into clinical studies in the U.S. The funds will also support the company’s efforts in finding new mechanisms for cancer immunotherapy and potential partners, it said.
Juno Diagnostics Inc. raised $25 million in a series A financing led by Perceptive Xontogeny Venture Fund. The company has earmarked the funds to support clinical validation studies of the company’s noninvasive prenatal testing (NIPT) solutions. The proceeds will also go toward product development and commercial launch of its NIPT products.
HONG KONG – Ultrasight Ltd. has closed a $13 million series B funding round, and is a step closer to entering the clinic in the U.S. with its cardiac ultrasound software. With the funds in hand, Rehovot, Israel-based Ultrasight aims to start clinical trials in the U.S. for its artificial intelligence (AI)-guided software for cardiac ultrasound.
Flare Therapeutics Inc. emerged from stealth mode with $82 million in series A financing and an ambitious agenda to systematically drug transcription factors associated with cancer and other neurological, genetic and immunological conditions.
Venture capitalists in China are adopting different models to quickly create value from biopharma companies and are able to exit much faster than their U.S counterparts, new data suggest.